Greater International Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Greater International Collaboration


Pharmaceutical Technology Europe


Stephanie Sutton
Medicine regulatory agencies in the EU, US and Australia have been successfully collaborating for some time now with regards to GMP inspections of API manufacturers, but now they are seeking to further expand this international effort by looking to include additional partners. The initial pilot scheme ran from 2008 to 2010 and involved the sharing of inspection plans, reports and information concerning API manufacturers, as well as several joint inspections. The project was so successful that cooperation in these areas has continued.

The current partners have agreed that clear criteria need to be established for any new participant to be accepted, as well as to maintain ongoing participation. To this end, the EMA has published a document entitled Programme to rationalise international GMP inspections of active pharmaceutical ingredients/active substances manufacturers that outlines the terms of reference and procedures for authorities to participate in the programme. Some of the points mentioned are that the reference GMP standard for inspections will be ICH Q7 and that participants will be responsible for ensuring that the appropriate confidentiality arrangements are in place. In addition, if an inspection results in regulatory action or license suspension, this decision will be shared with the other authorities.

However, if a potential new partner does not meet the criteria listed in the document, they may still be accepted into the programme for the benefit of global health. In addition, nonparticipating authorities may still request access to inspections information. In this case, information sharing will be facilitated in a way that does not compromise any confidential information.

The WHO has already agreed to become a new partner in the collaboration through its Prequalification of Medicines Programmes, which aims to make quality priority medicines available to those who need them and includes evaluation, inspection and quality monitoring activities.

Who will be next to take part?

Best wishes,
Stephanie Sutton
Community Manager

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology Europe,
Click here